

THE BIOTECH GROWTH TRUST PLC
Interim Management Statement – 3 months to 31 December 2009 (unaudited)

The Biotech Growth Trust PLC seeks capital appreciation through investment in the worldwide biotechnology industry principally by investing in emerging biotechnology companies.

Trust Characteristics

In the three month period ended 31 December 2009 the Company's net asset value per share fell by 1.6% compared to a fall of 0.3% in the Company's benchmark, the NASDAQ Biotechnology Index, measured in sterling terms. The Company's share price rose by 0.3% during the three-month period as the discount of share price to net asset value per share narrowed from 5.3% to 3.4%. No shares were repurchased by the Company for cancellation during the period. This performance was achieved against a background of a depreciating US\$ against sterling. The exchange rate at 30 September 2009 was 1.5994 compared to 1.6149 at 31 December 2009, a movement of 1%.

In the period from 31 December 2009 to 15 February 2010, the Company's net asset value per share rose by 6.8% and the share price by 8.0%. The Company's benchmark rose by 6.1% during the same period. During this period no shares were repurchased by the Company.

The fund raising that took place in December 2009 raised £23.9m of additional funds for the Company. 16,006,227 new ordinary shares were issued at a price of 149.18p per new ordinary share and following this the Company has 66,133,690 ordinary shares in issue. The net proceeds of the issue have been invested in accordance with the Company's investment policy.

Valuations remain attractive as healthcare stocks underperformed the general market in 2009, particularly post the announcement of the US healthcare reform proposals in late February. The Company's Investment Manager believes that this performance lag will close, particularly since some of the proposed reforms (for example lower prices) appear to be politically impossible to achieve. The rise in the Company's net asset value since the fundraising is in part explained by the receding threat of more radical reforms.

	31 December 2009	30 September 2009
Number of Holdings	41	36
Net Assets (£m)	100.3m	77.3m
Gearing (AIC basis)	100	100
Share Price (p)	146.50	146.00
NAV (p)	151.71	154.16
(Discount)/Premium	(3.4%)	(5.3%)

Source: Frostrow Capital LLP

Geographical Analysis

	% of portfolio at 31 December 2009	% of portfolio at 30 September 2009
North America	92.6	93.3
Continental Europe	3.0	2.9
Unquoted	1.5	1.6
UK Listed	2.9	2.2
Total	100.0	100.0

Source: Frostrow Capital LLP

10 Largest Investments

Name	% of portfolio at 31 December 2009	% of portfolio at 30 September 2009
Amgen	10.7	9.9
Celgene	8.3	10.1
Gilead Sciences	8.1	9.1
Curis	5.4	5.0
Dendreon	4.6	4.6
Genzyme	4.0	5.1
Thermo Fisher Scientific	3.5	2.9
Allos	3.4	1.7
Biogen Idec	3.3	4.5
Vertex	3.3	4.1
Total	54.6	57.0

Source: Frostrow Capital LLP

Performance to 31 December 2009

	3 Months	1 Year	3 Years	5 Years
Share Price	+0.3%	+19.8%	+30.2%	+73.4%
NAV per share	-1.6%	+12.8%	+32.5%	+49.8%
Benchmark*	-0.3%	+4.4%	+28.0%	+30.2%

Source: Morningstar

* Benchmark – NASDAQ Biotechnology Index measured in sterling terms.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide information to meet the requirements of the UK Listing Authority's Disclosure and Transparency Rules.

This Interim Management Statement is available on the Company's website www.biotechgt.com.

The Company's net asset value per share is announced daily and is available, together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Code:

Ordinary shares - 0038551

ISIN –

Ordinary Shares GB0000385517

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

17 February 2010